Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Onyx Weight Loss vs Somira Health

Onyx Weight Loss
Graded #359

Lower grade

vs+3.700000000000003
Somira Health
Graded #269

Higher grade

The verdict

Somira Health takes it — 62.5/100 to 58.8/100.

Somira Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Somira Health is a self-pay telehealth platform that connects you with independent licensed providers and compounding pharmacies for GLP-1 weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSomira Health +9
43
52
Dose & formulationEven
64
64
Clinical oversightSomira Health +2
75
77
Labs & monitoringOnyx Weight Loss +1
63
62
FulfillmentSomira Health +30
53
83
Contract termsOnyx Weight Loss +30
55
25
Onyx Weight Loss · left barSomira Health · right bar

The numbers

MetricOnyx Weight LossSomira Health
WeighScore58.8/10062.5/100
GradeCC
Scorecard rank#359#269
Semaglutide$228/mo (starting dose, compounded)$190/mo (compounded)
Tirzepatide$280/mo (starting dose, compounded)$285/mo (compounded)
Coverage8 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Onyx Weight Loss

Graded #359 · C

Strengths

  • Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
  • Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
  • Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
  • Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
  • Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team

Where it loses points

  • Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
  • No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
  • Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
  • Labs not included or mentioned; no baseline bloodwork protocol published
  • Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly
Somira Health

Graded #269 · C

Strengths

  • Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
  • Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
  • Free overnight shipping, with syringes and alcohol wipes included in every order
  • Simple, fast online intake reviewed by a licensed provider; no insurance required
  • Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide

Where it loses points

  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named
  • State-availability list is not published
  • No LegitScript certification displayed
  • New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard